Studies have elucidated the secretory and dimeric IgA structure (Bharathkar et al., 2020), and recent evidence has shown the advantages of IgA in virus-neutralizing (Sterlin et al., 2021; Sun et al., 2021; Göritzer et al., 2024) and cancer-killing (Brandsma et al., 2019) which highlights the potential of IgA in immunotherapy. Here, CD79A is linked to cancer.